SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs

• Published in: Frontiers in oncology Vol. 12; p. 840783
• Main Authors: Belluomini, Lorenzo, Calvetti, Lorenzo, Inno, Alessandro, Pasello, Giulia, Roca, Elisa, Vattemi, Emanuela, Veccia, Antonello, Menis, Jessica, Pilotto, Sara
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.04.2022
• Subjects: fragile patients; immune checkpoint inhibitors; immunotherapy; Oncology; predictive factor; small cell lung cancer (SCLC); fragile patients; immune checkpoint inhibitors; small cell lung cancer (SCLC); immunotherapy; predictive factor
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.840783

Small cell lung cancer (SCLC) represents about 13%-15% of all lung cancers. It has a particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage (extended disease). Three phase III studies tested the combination of immunotherapy (atezolizumab, durvalumab with or without tremelimumab, and pembrolizumab) with double platinum chemotherapy, with practice-changing results. However, despite the high tumor mutational load and the chronic pro-inflammatory state induced by prolonged exposure to cigarette smoke, the benefit observed with immunotherapy is very modest and most patients experience disease recurrence. Unfortunately, biological, clinical, or molecular factors that can predict this risk have not yet been identified. Thanks to these clinically meaningful steps forward, SCLC is no longer considered an "orphan" disease. Innovative treatment strategies and combinations are currently under investigation to further improve the expected prognosis of patients with SCLC. Following the recent therapeutic innovations, we have reviewed the available literature data about SCLC management, with a focus on current unmet needs and potential predictive factors. In detail, the role of radiotherapy; fragile populations, such as elderly or low-performance status patients (ECOG PS 2), usually excluded from randomized studies; predictive factors of response useful to optimize and guide therapeutic choices; and new molecular targets and future combinations have been explored and revised.